Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say - Reuters
Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNRXcwd2ZTOXFZNXBqRlU5ZERTQkVXYW1BZDFpZFpNOXVEdEk1V3pDUEdpa0FadURxcGYtMVNjRHRBSkxoWDdxcWtBcERNVUdaYkU1d1lCWlFMT1dkX3pHOVp1dnUtSko3aERhaDh5UElCd0RlcWpOQmIwNVdHbmJiUWQyZjNOQlY3QUhRWHV1N3h1QnFNdUhVemo2UkltZF9NeklhWjRmNWVuZ2ZfUEJ2Z2dmVnR3Z29N?oc=5" target="_blank">Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say</a> <font color="#6f6f6f">Reuters</font>
Dr Reddy's Laboratories plans to launch its generic semaglutide injection, potentially named Obeda, in India by March 2026, following the patent expiry of semaglutide. The company aims to price it competitively, potentially up to 60% below the branded product.
Dr Reddy's Laboratories has applied to trademark the brand name 'Obeda' for its upcoming generic version of semaglutide, the active ingredient in Novo Nordisk's Ozempic. The launch is anticipated in March 2026, coinciding with the patent expiry of semaglutide in India.
Similar Stories
Related coverage based on topic and tags
Teva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Teva wins FDA approval for monthly schizophrenia injection Weltruza Reuters
October 9, 2026 at 11:47 AMArgenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
October 8, 2026 at 08:49 PMWHO endorses lifestyle changes over GLP-1 drugs in child obesity fight - Reuters
WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight Reuters
October 7, 2026 at 07:39 AMViatris bets on non-opioid pain drugs with $1.65 billion Pacira deal - Reuters
Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal Reuters
October 8, 2026 at 02:39 PMUS FDA flags four deaths in Newron's schizophrenia drug studies - Reuters
US FDA flags four deaths in Newron's schizophrenia drug studies Reuters
October 8, 2026 at 05:47 PMUS FDA expands use of Novartis drug for chronic skin condition - Reuters
US FDA expands use of Novartis drug for chronic skin condition Reuters
October 7, 2026 at 04:51 PM